Report / Tech
Published by NOISE
Moderna and Merck mRNA vaccine cuts melanoma death and recurrence by 42%
From Morning NOISE.
Moderna and Merck announced their personalized mRNA cancer vaccine combined with Keytruda cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial. Among 1,137 patients with surgically removed stage IIB-IV melanoma, 82% of those on the vaccine combination were alive without recurrence after two years, versus 70% receiving Keytruda alone. The results, scheduled for presentation at the European Society of Medical Oncology meeting in Madrid, are the first late-stage evidence of an mRNA vaccine improving outcomes over standard-of-care immunotherapy. The companies are discussing approval with regulators.
Saved versions
These dates record changes to NOISE’s copy. They are not event dates.